James Ruggles

James Ruggles is an accomplished medical affairs executive currently serving as Executive Director at Ionis Pharmaceuticals, Inc., where responsibilities include establishing Medical Affairs and supporting the launch of donidalorsen for hereditary angioedema. Ruggles has extensive experience in the pharmaceutical industry, having held key leadership positions at AstraZeneca as Executive Director of Medical for Diabetes Injectables, and at Bristol-Myers Squibb as US Medical Lead for the exenatide franchise. Earlier roles at Amylin Pharmaceuticals encompassed various leadership responsibilities in medical plans and operations, alongside significant contributions to scientific disclosures and medical writing. Ruggles' academic foundation includes a PhD in Chemistry and Biochemistry from the University of Colorado Boulder and a postdoctoral fellowship in the same field, complemented by dual undergraduate degrees in Chemistry and Biology from New Mexico State University.